Group 1: Oil and Gas Sector - Oil stocks experienced a decline, with Sinopec (00386) down 3.89%, PetroChina (00857) down 3.17%, and CNOOC (00883) down 2.79%. This follows a drop in WTI crude oil futures by 2.77% to $62.84 per barrel and Brent crude by 2.71% to $67.52 per barrel [1] Group 2: Renewable Energy Sector - Solar stocks fell collectively, with Xinyi Solar (00968) down 3.62% and New Special Energy (01799) down 3.61%. The rise in silver prices has increased silver paste costs, impacting the battery and component sectors [1] Group 3: Precious Metals Sector - Lao Poo Gold (06181) saw a nearly 5% drop. Bank of America Securities reported that the company is expected to benefit from rising gold prices, with a projected revenue increase of 165% year-on-year for the second half of last year [1] Group 4: Pharmaceuticals - Zai Lab (09688) rose by 7% after its injection drug ZL-1310 was proposed for breakthrough therapy designation for extensive-stage small cell lung cancer (ES-SCLC), showing promising early clinical data [2] Group 5: Precision Manufacturing - China High Precision (00591) fell over 18% after issuing a profit warning, expecting a profit of approximately RMB 2.5 million to RMB 4.5 million for the six months ending December 31, 2025, due to project delays in the oil and petrochemical sectors [2] Group 6: Non-Ferrous Metals - Non-ferrous stocks faced significant declines, with China Nonferrous Mining (01258) down 5.08% and Zijin Mining (02899) down 5.29%. This is attributed to a "de-risking" sentiment in global financial markets, leading to a sell-off in precious metals [3] Group 7: Biotechnology - Xiansheng Pharmaceutical (02096) increased over 4.4% after announcing a licensing agreement with AbbVie for the investigational drug SIM0500, which includes upfront payments and potential milestone payments totaling up to $1.055 billion [3] Group 8: Gaming Sector - Gaming stocks declined, with Melco International Development (00200) down 6.21%. Wynn Macau reported a 7% year-on-year drop in EBITDA for Q4 2025, which was below market expectations [4] Group 9: Oilfield Services - Anton Oilfield Services (03337) rose over 9% after announcing a profit forecast of approximately RMB 360 million to RMB 380 million for 2025, representing a significant year-on-year increase of 48.4% to 56.6% [4] Group 10: U.S. Market Movements - Arko Petroleum (APC.US) opened with a 2.5% decline after its market debut. The company delivered 1.5 billion gallons of fuel in the nine months ending September 30, 2025 [5] - Albemarle (ALB.US) fell 9.41% despite a 16% year-on-year increase in Q4 sales to $1.4 billion, reporting a net loss of $414 million [5] - Boeing (BA.US) rose 1.31% as it plans to increase the monthly production of its 737 series aircraft to 63 units in the coming years [5] Group 11: Technology Sector - Cisco (CSCO.US) dropped 12.32% as it projected a decline in adjusted gross margin for Q3, indicating a worsening trend compared to previous quarters [7] - Storage stocks saw gains, with SanDisk (SNDK.US) up 5.16% and Western Digital (WDC.US) up 3.78% [7]

Core Viewpoint - Sihuan Pharmaceutical (02096) has seen its stock price increase by over 3%, currently trading at HKD 12.61, with a transaction volume of HKD 22.0187 million, following the announcement of a licensing agreement with AbbVie Inc. for the investigational drug SIM0500 [1] Group 1: Licensing Agreement - The agreement with AbbVie includes an upfront payment and potential milestone payments totaling up to USD 1.055 billion, along with tiered royalties based on net sales [1] - Sihuan Pharmaceutical's core product SIM0500 has received a USD 40 million milestone payment from AbbVie, indicating strong progress in its development [1] Group 2: Clinical Development - SIM0500 has been granted Fast Track designation by the FDA, with Phase I clinical data expected to be released within the year, aiming for concept validation [1] - The drug has demonstrated significantly superior anti-tumor activity compared to dual-antibody TCEs in preclinical studies, leading the global progress among competitors targeting the same pathway [1] Group 3: Innovation and Collaboration - The company’s innovative research and development system and platform technology capabilities continue to be validated, having secured multiple overseas licensing agreements valued at USD 1 billion [1]

Core Viewpoint - Xiansheng Pharmaceutical (02096) has seen a stock increase of over 3%, currently trading at HKD 12.61 with a transaction volume of HKD 22.0187 million, following the announcement of an overseas licensing option agreement with AbbVie Inc. for the investigational drug SIM0500 [1] Group 1 - The agreement with AbbVie includes an upfront payment and potential milestone payments totaling up to USD 1.055 billion, along with tiered royalties based on net sales [1] - Xiansheng Pharmaceutical's core product SIM0500 has received a USD 40 million milestone payment from AbbVie, and the drug has been granted Fast Track designation by the FDA [1] - The company is expected to report Phase I clinical data and achieve proof of concept within the year, indicating strong progress in its innovative research and development capabilities [1] Group 2 - SIM0500 has demonstrated significantly superior anti-tumor activity compared to dual-antibody TCEs in preclinical studies and is leading in global progress among competitors targeting the same pathway [1] - The company has successfully established multiple overseas licensing collaborations valued at USD 1 billion, showcasing its robust platform technology and innovation in drug development [1]

Core Viewpoint - The company is undergoing a continuous innovation transformation, with multiple innovative pipelines being launched internationally, leading to an upward revision of revenue and profit forecasts for 2026 while maintaining profit forecasts for 2025 and 2027 [1] Group 1: Financial Analysis - The revenue projections for 2025, 2026, and 2027 are adjusted to 76.3 billion, 100.3 billion, and 110.4 billion respectively, up from previous estimates of 76.3 billion, 91.0 billion, and 110.4 billion [1] - The net profit attributable to the parent company for 2025, 2026, and 2027 is revised to 11.5 billion, 16.5 billion, and 16.6 billion respectively, compared to earlier estimates of 11.5 billion, 13.8 billion, and 16.6 billion [1] - The corresponding EPS for 2025, 2026, and 2027 is adjusted to 0.44, 0.64, and 0.64 respectively, up from previous estimates of 0.44, 0.53, and 0.64 [1] Group 2: Product Development - The company received a milestone payment of 40 million USD from AbbVie for SIM0500 on February 3, 2026, following a licensing agreement signed in January 2025 [1] - SIM0500 is a humanized TCE tri-antibody targeting two tumor-associated antigens, showing strong T-cell cytotoxic effects against multiple myeloma cells [2] - The FDA granted SIM0500 a fast track designation for use in patients with multiple myeloma who have received at least three prior lines of therapy and are resistant or intolerant to standard treatments [2] Group 3: Strategic Partnerships - Since 2025, the company has successfully licensed four pipelines internationally, including agreements with AbbVie, NextCure, Ipsen, and Boehringer Ingelheim, with potential total payments reaching up to 10.6 billion USD and 10.16 billion EUR [3] - The partnerships with major multinational corporations (MNCs) validate the company's enhanced innovation capabilities and suggest ongoing opportunities for new business development in the future [3]

Core Viewpoint - The company, Xiansheng Pharmaceutical (02096), is intensifying its innovative transformation with multiple innovative pipelines being launched internationally. The revenue and profit forecasts for 2026 have been raised due to the confirmation of upfront and milestone payments, while the 2025 and 2027 profit forecasts remain unchanged. The expected revenues for 2025-2027 are 7.63 billion, 10.03 billion, and 11.04 billion yuan respectively, with net profits of 1.15 billion, 1.65 billion, and 1.66 billion yuan, maintaining a "Buy" rating [1]. Business Analysis - On February 3, 2026, the company announced receiving a recent milestone payment of 40 million USD from AbbVie related to SIM0500 (GPRC5D/BCMA/CD3 tri-antibody). In January 2025, the company signed an overseas licensing option agreement with AbbVie for SIM0500, which includes an upfront payment and potential payments up to 1.055 billion USD, along with tiered royalties based on net sales outside Greater China [1][2]. - SIM0500 is a humanized TCE tri-antibody targeting two tumor-associated antigens, showing promising efficacy. It combines a low-affinity but highly targeted CD3 antibody with two anti-tumor-associated antibodies, GPRC5D and BCMA, demonstrating strong T-cell cytotoxic effects against multiple myeloma (MM) cells. In April 2024, SIM0500 received Fast Track designation from the FDA for patients with relapsed or refractory MM who have received at least three prior lines of therapy [1]. Innovation Transformation - Since 2025, the company has successfully licensed out four pipelines, including: 1. SIM0500 with AbbVie for licensing rights 2. SIM0505 (CDH6ADC) with NextCure, potentially yielding 745 million USD in related payments 3. SIM0613 (LRRC15ADC) with Ipsen, with a total transaction payment potential of 1.06 billion USD 4. SIM0709 (TL1A/IL-23 dual antibody) with Boehringer Ingelheim, which includes an upfront payment of 42 million euros and potential milestone payments up to 1.016 billion euros based on development progress and commercialization [2]. - The successful out-licensing of self-developed pipelines further validates the company's enhanced innovative R&D capabilities, with recognition from major multinational corporations (MNCs). There remains potential for continued new business development (BD) opportunities for numerous self-developed pipelines and innovative ADC platforms in the future [2].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [7]. Core Insights - The company has achieved significant business development (BD) progress, enhancing both the breadth and depth of its self-developed new drugs. Recent collaborations with major pharmaceutical companies indicate a strong pipeline and potential for revenue growth [4]. - The financial forecast predicts total revenue growth from 66.40 billion CNY in 2023 to 104.27 billion CNY by 2027, with a compound annual growth rate (CAGR) of approximately 16% [4][6]. - The net profit attributable to shareholders is expected to rise from 7.15 billion CNY in 2023 to 16.09 billion CNY in 2027, reflecting a significant increase in profitability [4][6]. Financial Summary - Revenue projections for the company are as follows: 6,640 million CNY in 2023, 6,635 million CNY in 2024, 7,690 million CNY in 2025, 9,009 million CNY in 2026, and 10,427 million CNY in 2027, with year-over-year growth rates of 4%, 0%, 16%, 17%, and 16% respectively [3][4]. - The net profit forecast shows a decline of 23% in 2023, followed by a recovery with growth rates of 3%, 63%, 16%, and 16% in the subsequent years [3][4]. - Earnings per share (EPS) are projected to increase from 0.28 CNY in 2023 to 0.62 CNY in 2027, indicating a positive trend in shareholder returns [3][4]. Business Development Highlights - The company has secured multiple partnerships, including a recent agreement with AbbVie for clinical development collaboration, which includes a payment of 40 million USD [4]. - A licensing agreement with Boehringer Ingelheim for a dual-specific antibody is expected to generate up to 1.016 billion EUR in milestone payments, showcasing the company's strong position in the market [4]. - The company is also advancing its ADC (antibody-drug conjugate) pipeline, with significant collaborations that enhance its competitive edge in the industry [4].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.82 [1][5]. Core Insights - The company has received a milestone payment of USD 40 million from AbbVie for SIM0500, indicating positive progress in clinical development, with expectations to read out Phase I clinical data within the year [1][2]. - SIM0500, a tri-antibody TCE targeting BCMA/GPRC5D/CD3, is currently in Phase I clinical trials in both China and the US, with the US expected to complete its first patient dosing by mid-2025 [2]. - The company has established a strong pipeline with multiple billion-dollar business development (BD) agreements, validating its innovative research and development capabilities [1][4]. Summary by Sections Clinical Development - SIM0500 has shown superior anti-tumor activity in preclinical studies compared to dual-antibody TCEs, with early clinical data from competitors indicating promising results [3]. - The company is leading in global progress among competitors, with only one competitor molecule in Phase III and others in early development stages [2][3]. Product Pipeline and Global Expansion - The company is advancing its innovative systems towards proof of concept (PoC), with SIM0500 validating the TCE platform's value [4]. - Other products like SIM0613 and SIM0505 are also progressing in global markets, with SIM0505 in Phase I trials and expected to read out initial data within the year [4]. - The company is exploring new therapeutic areas, including autoimmune diseases, with promising candidates like SIM070 and SIM0278 [4]. Financial Projections and Valuation - The company’s revenue projections for 2025, 2026, and 2027 are set at RMB 7.646 billion, RMB 8.714 billion, and RMB 9.264 billion respectively, with adjusted net profits expected to be RMB 1.244 billion, RMB 1.476 billion, and RMB 1.568 billion [10][11]. - The estimated EPS for 2025, 2026, and 2027 is RMB 0.45, RMB 0.54, and RMB 0.59, respectively, with a maintained PE ratio of 33x for 2026 [5][11].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.82 [1][5][11] Core Insights - The company has received a milestone payment of USD 40 million from AbbVie for SIM0500, indicating positive progress in clinical development [1][2] - SIM0500 is expected to read out Phase I clinical data within the year, with the drug showing superior anti-tumor activity in preclinical studies compared to other competitors [2][3] - The company is advancing its product pipeline globally, with several products expected to achieve proof of concept (PoC) and initial clinical data this year [4] Financial Projections - The company’s revenue is projected to reach RMB 7.646 billion in 2025, with a compound annual growth rate (CAGR) of 14% from 2025 to 2027 [5][11] - Adjusted net profit forecasts for 2025, 2026, and 2027 are RMB 11.8 billion, RMB 14.0 billion, and RMB 15.2 billion respectively [5][11] - The earnings per share (EPS) estimates are RMB 0.45, RMB 0.54, and RMB 0.59 for 2025, 2026, and 2027 respectively [5][11] Product Development and Pipeline - SIM0500 is a tri-antibody TCE that has received FDA Fast Track Designation and is currently in Phase I clinical trials in both China and the US [2][3] - The company is also advancing other products such as SIM0613 and SIM0505, with the latter expected to read out initial data this year [4] - The ADC platform and other innovative therapies are positioned to enhance the company's global competitiveness [4]

Core Viewpoint - Recently, the company announced that it received a payment of $40 million from AbbVie as part of a milestone payment under the overseas licensing option agreement for the investigational new candidate drug SIM0500 [1] Group 1: Financial Details - The agreement includes an upfront payment and potential milestone payments totaling up to $1.055 billion [1] - The company will also receive tiered royalties based on net sales [1] Group 2: Development Progress - The receipt of this payment signifies positive progress in the clinical development collaboration between the company and AbbVie for SIM0500 [1]

Group 1: Agricultural Policy and Industry - The Central Committee and State Council of China issued a document promoting the enhancement and efficiency of the "vegetable basket" industry, emphasizing the need for a diversified food supply system [1] - The document outlines measures to stabilize pig production, support the dairy industry, and promote the consumption of dairy products [1] - It also encourages the development of silage corn and alfalfa production, modernizes facility agriculture, and strengthens food safety regulations [1] Group 2: Market Performance and Trends - In January, the sales volume of home appliances and digital products under the old-for-new policy exceeded 15 million units, generating nearly 59 billion yuan in sales [5] - Hong Kong's property market saw a year-on-year increase of 55.8% in building sale contracts, with a total value of 57.2 billion HKD [6] - Longyuan Aviation reported a 24.6% year-on-year increase in global sales of its pickup trucks, totaling 15,350 units in January [10] Group 3: Corporate Developments - Xiansheng Pharmaceutical received a milestone payment of 40 million USD from AbbVie as part of their licensing agreement for the SIM0500 antibody [8] - InnoScience completed significant design integration for its products on Google's AI hardware platform and signed a compliance supply agreement [12] - ZTE Corporation has not yet initiated its planned share buyback of 1 billion to 1.2 billion yuan, which was approved in December 2025 [7]